

STAMPEDE Abiraterone Chartered Criteria (All M1 patients)		ADT Alone	ADT + AAP			
		No. of events/ No. of patients		Adjusted HR (95% CI)		Interaction between metastatic subgroups p-value
<b>Overall Survival</b>						
	Overall	195/452	135/449		0.61 (0.49-0.79)	
	Low	53/196	39/206		0.64 (0.42-0.97)	
	High	142/256	96/243		0.60 (0.46-0.78)	0.77
<b>Failure Free Survival</b>						
	Overall	354/452	191/449		0.32 (0.26-0.37)	
	Low	133/196	57/206		0.26 (0.19-0.36)	
	High	221/256	134/243		0.33 (0.26-0.41)	0.47
<b>Skeletal Related Events</b>						
	Overall	164/452	93/449		0.47 (0.36-0.60)	
	Low	46/196	25/206		0.46 (0.28-0.75)	
	High	118/256	68/243		0.47 (0.35-0.63)	0.98
<b>Progression Free Survival</b>						
	Overall	267/452	158/449		0.45 (0.37-0.54)	
	Low	86/196	45/206		0.40 (0.28-0.58)	
	High	181/256	113/243		0.46 (0.36-0.58)	0.67
<b>Prostate Cancer Specific Death</b>						
	Overall	172/452	114/449		0.59 (0.46-0.75)	
	Low	43/196	31/206		0.63 (0.39-1.01)	
	High	129/256	83/243		0.58 (0.44-0.76)	0.74

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2

Favours ADT + AAP



Favours ADT